For Health Care Professionals Outside the US
Find a Centre
Find a Centre
DLBCL1
I Am KYMRIAH

Because

I want to empower my own immune system to fight DLBCL1
I need a CAR-T treatment with proven efficacy and a manageable safety profile
I refuse to give up hope

KYMRIAH® (tisagenlecleucel) is indicated for the treatment of:
  • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
  • Paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
KYMRIAH, the first approved CAR-T therapy to utilise the 4-1BB domain, demonstrates durable and sustained responses in relapsed or refractory DLBCL1
  • High rates of durable responses where other therapies have failed
  • First approved CAR-T to utilise the 4-1BB costimulatory domain
  • Flexibility of cryopreservation and convenience of outpatient experience
Reference:
  • 1.Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2020.